PTSD

WCI Health LLC, Your Alternative Health and Wellness Hub Will Be a Vendor and Presenter at Wonderland Miami by Microdose

Retrieved on: 
Wednesday, October 5, 2022

According to the Centers for Disease Control and Prevention, mental illness has become a big problem both in the United States and growing globally.

Key Points: 
  • According to the Centers for Disease Control and Prevention, mental illness has become a big problem both in the United States and growing globally.
  • WCI Health & WCI Health University's objective is to bring alternative health and wellness options to people through our quality plant-based products and educational programs.
  • At WCI Health, we help you level up your wellness journey using the healing powers of plant medicine!
  • Contact Dr. Lola to Sponsor WCI Health' BOOTH & PODCAST:

Horizons, Psychedelic Community's Largest and Longest-running Conference, to Hold its 15th Edition in New York City on October 12-16

Retrieved on: 
Wednesday, October 5, 2022

NEW YORK, Oct. 5, 2022 /PRNewswire/ -- Horizons, the world's longest-running annual event devoted to psychedelics, returns to the New York Academy of Medicine and The Great Hall at The Cooper Union from Wednesday, October 12 – Sunday, October 16, 2022.

Key Points: 
  • This year's program includes two days of classes for medical and care professionals, as well as four days of in-depth forums that explore the field of psychedelics.
  • Since 2007, Horizons has helped the public understand the world of psychedelics through live events and digital media.
  • Its flagship conference in New York City is the largest and longest-running annual gathering of the psychedelic community in the world.
  • Horizons is produced by Horizons PBC, a public benefit corporation based in New York City.

Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects

Retrieved on: 
Wednesday, October 5, 2022

Alzamend is also pursuing AL001 for the treatment of bipolar disorder, MDD and PTSD.

Key Points: 
  • Alzamend is also pursuing AL001 for the treatment of bipolar disorder, MDD and PTSD.
  • As the safety and tolerability of AL001 would need to be tested in healthy and elderly adults before Alzamend could initiate later-stage testing of AL001 for bipolar disorder, MDD and PTSD, the addition of healthy and elderly adults to the on-going AL001-02 clinical trial would expedite the timing of further clinical trials.
  • Alzamend will test AL001 in four healthy adult and elderly adult cohorts of eight subjects under MAD conditions.
  • AL001 has the potential to deliver benefits of marketed lithium carbonate while mitigating or avoiding current toxicities associated with lithium.

Exploring New Pathways of Discovery for Eating Disorders - A Free Webinar from the Brain & Behavior Research Foundation

Retrieved on: 
Tuesday, October 4, 2022

New York, Oct. 04, 2022 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, Exploring New Pathways of Discovery for Eating Disorders on Tuesday, October 11, 2022, at 2:00 pm EDT.

Key Points: 
  • New York, Oct. 04, 2022 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, Exploring New Pathways of Discovery for Eating Disorders on Tuesday, October 11, 2022, at 2:00 pm EDT.
  • Dr. Khalsa discusses how interoception is critical to understanding how crosstalk between the gut and brain influences eating disorders.
  • This webinar is part of a series of free monthly Meet the Scientist webinars on the latest developments in psychiatry offered by the Brain & Behavior Research Foundation.
  • The Brain & Behavior Research Foundation awards research grants to develop improved treatments, cures, and methods of prevention for mental illness.

Adam Seidner MD MPH, Chief Medical Officer at The Hartford and Medical Policy Expert, Joins Harvard MedTech’s Medical Advisory Board

Retrieved on: 
Tuesday, October 4, 2022

Adam Seidner, M.D., a thought leader in medical policy development with a particular focus on Workers Compensation and Disability Management, has been appointed to the Medical Advisory Board of Harvard MedTech .

Key Points: 
  • Adam Seidner, M.D., a thought leader in medical policy development with a particular focus on Workers Compensation and Disability Management, has been appointed to the Medical Advisory Board of Harvard MedTech .
  • Dr. Seidners expertise in public health issues, coupled with his experience in employee health initiatives, make him a valuable addition to Harvard MedTechs Medical Advisory Board, said Gerry Stanley, M.D., Chief Medical Officer, Harvard MedTech.
  • We look forward to his innovative approach as a member of our Medical Advisory Board.
  • Dr. Seidner has served as Chief Medical Officer at The Hartford since 2017.

MAPS PBC Elects Jeff George as Chairman of the Board of Directors

Retrieved on: 
Tuesday, October 4, 2022

Jeff George brings over two decades of experience in global healthcare and corporate leadership across North America, Europe and emerging markets.

Key Points: 
  • Jeff George brings over two decades of experience in global healthcare and corporate leadership across North America, Europe and emerging markets.
  • Mr. George serves on multiple boards of directors for public and private biopharmaceutical and medical device companies and non-profit organizations.
  • Founded in 2014, MAPS PBC is a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit organization.
  • MAPS PBC is the parent company of MAPS EU, formed to organize and administer clinical trials of MDMA-assisted therapy for PTSD in the United Kingdom and European Union.

Tryp Therapeutics Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin

Retrieved on: 
Monday, October 3, 2022

KELOWNA, British Columbia, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the World Intellectual Property Organization (WIPO) published their international patent application (PCT/IB2022/052347) covering the intravenous administration of psilocybin and psilocin. The PCT application, titled “Improved Methods For The Use of Psychedelics” expands and strengthens the IP related to the Company’s development of TRP-8803, an IV formulation of psilocin, which will be administered in conjunction with psychotherapy.

Key Points: 
  • Psilocybin is a pro-drug which needs to be converted to psilocin, the active molecule that crosses the blood brain barrier and induces the psychedelic state.
  • These factors contribute to variable blood levels of psilocin, which can be either too low or too high.
  • Conversely, should the patient experience a side effect, the clinician can terminate administration of the drug, an option not available with oral administration.
  • Orally administered psychedelics have been widely introduced for use in treating depression, PTSD, OCD and other conditions, including by Tryp Therapeutics and its TRP-8802 programs.

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology

Retrieved on: 
Monday, October 3, 2022

ENGLEWOOD CLIFFS, NJ, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it is working with Premier Consulting as its regulatory partner to assist with the preparation of a pre-Investigational New Drug (IND) package and meeting request with the United States Food and Drug Administration (FDA) for a novel topical formulation of ketamine, designated as SPC-26, for the treatment of fibromyalgia.

Key Points: 
  • Premier Consulting will assist the Company with the development of its nonclinical, clinical, clinical pharmacology, and biopharmaceutics strategy and program to be proposed to the FDA.
  • The submission of a pre-IND meeting request for collaborative discussions with the FDA will be made in anticipation of the filing a clinical IND package.
  • We are confident that our highly constructive pre-clinical work on SP-26 will offer strong support for our pre-IND package as we seek to advance our time-released ketamine delivery system into the clinic, said CEO Eric Weisblum.
  • Fibromyalgia is a chronic condition causing pain to the connective tissues through the body including muscles, ligaments, and tendons.

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option

Retrieved on: 
Friday, September 30, 2022

Silo Pharmas common stock began trading on the Nasdaq Capital Market under the symbol SILO on September 27, 2022.

Key Points: 
  • Silo Pharmas common stock began trading on the Nasdaq Capital Market under the symbol SILO on September 27, 2022.
  • The gross proceeds from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Silo Pharma, were $5,750,000 million.
  • Silo Pharma intends to use the net proceeds from the offering for product development, marketing, and working capital and general corporate purposes.
  • A portion of the proceeds may also be used for acquisitions of complementary businesses, technologies, or other assets.

Break the Silence; New Intensive Online Program to Help PTSD, Trauma and Anxiety

Retrieved on: 
Thursday, September 29, 2022

SCOTTSDALE, Ariz., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Purple Heart Behavioral Health LLC, a premier telepsychology trauma service, announced today an innovative program for PTSD, Anxiety and Stress treatment.

Key Points: 
  • SCOTTSDALE, Ariz., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Purple Heart Behavioral Health LLC, a premier telepsychology trauma service, announced today an innovative program for PTSD, Anxiety and Stress treatment.
  • The program is a 5-week intensive online program that includes various treatments that have scientific empirical evidence to be effective in treating PTSD, anxiety and stress.
  • This innovative new online program offers treatments that have been scientifically shown to be effective in helping people overcome these difficulties.
  • She is an Army Veteran and was later trained by the Department of Defense to treat trauma, anxiety, stress, and other mental health challenges.